Anavex 2-73 Improves PD Symptoms, Study Says

Initially, biopharmaceutical company Anavex Life Sciences ("Anavex") developed Anavex 2-73 (blarcamesine) for patients with Alzheimer's disease. Now, the company has expanded its exploration of the therapy to determine its efficacy…

Continue Reading Anavex 2-73 Improves PD Symptoms, Study Says

Study: NUPLAZID as a Treatment for Parkinson’s Disease

ACADIA Pharmaceuticals has released data on NUPLAZID, a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. This treatment is meant to treat Parkinson's disease patients, specifically the delusions…

Continue Reading Study: NUPLAZID as a Treatment for Parkinson’s Disease